Why did CLEDUCATE.BO stock fall so sharply on 09 Feb 2026?

The fall followed weak earnings metrics and investor selling after the 02 Feb 2026 earnings cycle. EPS is negative at -1.34 and leverage is high, prompting sharper downside on the BSE close at INR 58.55.

What are the near-term technical signals for CLEDUCATE.BO stock?

Short-term indicators are oversold: RSI **37.21**, CCI **-141.34**, and MACD negative. Watch for a move above INR 70.00 and rising volume to confirm a trend reversal.

What price targets and forecasts exist for CLEDUCATE.BO stock?

Meyka AI's 12-month forecast is INR 96.47, implying **64.79%** upside from INR 58.55. Conservative near-term target is INR 70.00 and downside support sits near INR 55.00. Forecasts are not guarantees.

Is CLEDUCATE.BO stock a value play versus its sector?

On multiples, CLEDUCATE.BO looks cheaper with PB **1.16** and P/S **0.67**, while the Consumer Defensive peer PB is about **4.06**. Still, negative ROE and volatile earnings raise valuation risk.

IN Stocks

CLEDUCATE.BO stock drops 19.81% on BSE on 09 Feb 2026: key recovery signs

ByDanny Kontos February 9, 2026February 9, 2026

CLEDUCATE.BO stock plunged 19.81% to INR 58.55 on the BSE at close on 09 Feb 2026, making it one of the session’s top losers. The sharp move followed recent earnings and left price sitting near the 52-week low of INR 58.41. Volume rose to 12,684.00 shares versus an average of 9,656.00, flagging outsized selling. Investors should weigh weak EPS and elevated leverage against a modest book value and cash per share before deciding a strategy.